The Study of Vancomycin Use and Its Adverse Reactions Associated to Patients of a Brazilian University Hospital

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2011 Jul 19

PMID 21762507

Citations 19

Authors

Daniel Savignon Marinho

Gisele Huf

Bruno L A Ferreira

Helena Castro

Carlos R Rodrigues

Valeria Pereira de Sousa

Lucio M Cabral

Affiliations

Soon will be listed here.

Abstract

Background: Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage profile must be evaluated to assure maximum benefit and minimum risk.

Findings: A cross-sectional retrospective study was carried out among inpatients that received vancomycin in a Brazilian quaternary hospital. The occurrence of adverse reactions reported was evaluated in medical records relating to patients taking vancomycin during a one year period. Males comprised 52% (95% CI: 41.7-60.2%) of the sample population, with a mean age of 50.6 (95% CI: 47.2-54.0) years and mean treatment period of 9.7 (95% CI: 8.0-11.5) Days. It was verified that nephrotoxicity occurred in 18.4% (95% CI: 11.3-27.5) of patients, Red man syndrome occurred in 2% (95% CI 0.2-7.2), while the occurrence of thrombocytopenia was 7.1% (95% CI: 2.9-14.2).

Conclusions: It may be noted that even after 50 years of use, adverse reactions associated with vancomycin continue with high frequency, presenting a public health problem, especially considering its current use in cases of multidrug resistant infections. In this context, we emphasize the importance of intensive pharmacovigilance in hospital as a surveillance tool after drug approval by the sanitary authority.

Citing Articles

Incidence and risk factors of Vancomycin-induced thrombocytopenia: a six-year real-world study.

Zhu Y, Huang L, Zhang J, Liang L, Jin P BMC Infect Dis. 2025; 25(1):7.

PMID: 39748286 PMC: 11697819. DOI: 10.1186/s12879-024-10393-1.

Drug-Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians.

Hincu S, Apetroaei M, Stefan G, Faca A, Arsene A, Mahler B Pharmaceutics. 2024; 16(9).

PMID: 39339174 PMC: 11434876. DOI: 10.3390/pharmaceutics16091137.

Susceptibility of to Anti-Inflammatory Drugs with a Focus on the Combinatory Effect of Celecoxib with Oxacillin In Vitro.

Okpala O, Rondevaldova J, Osei-Owusu H, Kudera T, Kokoskova T, Kokoska L Molecules. 2024; 29(15).

PMID: 39125072 PMC: 11314137. DOI: 10.3390/molecules29153665.

Appropriateness of antimicrobial selection for treatment of pneumonia in selected public hospitals of Eastern Ethiopia: A cross-sectional study.

Jambo A, Edessa D, Adem F, Gashaw T SAGE Open Med. 2023; 11:20503121231163792.

PMID: 37065976 PMC: 10102944. DOI: 10.1177/20503121231163792.

A rare case of infant eosinophilia induced by oral vancomycin: a case report and literature review.

Wu Y, Yin W, Guo S, Wang F J Int Med Res. 2023; 51(2):3000605231156761.

PMID: 36852821 PMC: 9983108. DOI: 10.1177/03000605231156761.

References

Rybak M, Albrecht L, Boike S, Chandrasekar P . Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25(4):679-87. DOI: 10.1093/jac/25.4.679. View

Sahai J, Healy D, Garris R, Berry A, Polk R . Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis. 1989; 160(5):876-81. DOI: 10.1093/infdis/160.5.876. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Rybak M, Bailey E, Warbasse L . Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob Agents Chemother. 1992; 36(6):1204-7. PMC: 190318. DOI: 10.1128/AAC.36.6.1204. View

Beringer P, Wong-Beringer A, Rho J . Predictive performance of a vancomycin-aminoglycoside population model. Ann Pharmacother. 1998; 32(2):176-81. DOI: 10.1345/aph.17129. View

Karch F, Lasagna L . Adverse drug reactions. A critical review. JAMA. 1975; 234(12):1236-41. View

von Drygalski A, Curtis B, Bougie D, McFarland J, Ahl S, Limbu I . Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007; 356(9):904-10. DOI: 10.1056/NEJMoa065066. View

Vidal C, Gonzalez Quintela A, Fuente R . Toxic epidermal necrolysis due to vancomycin. Ann Allergy. 1992; 68(4):345-7. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

10.

Rotschafer J, Gilliland S, Rodvold K, FitzGerald C, Guay D . A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J Antimicrob Chemother. 1994; 33(4):811-21. DOI: 10.1093/jac/33.4.811. View

11.

Healy D, Sahai J, Fuller S, Polk R . Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990; 34(4):550-4. PMC: 171642. DOI: 10.1128/AAC.34.4.550. View

12.

Bailey P, Gray H . An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report. Cases J. 2008; 1(1):111. PMC: 2527496. DOI: 10.1186/1757-1626-1-111. View

13.

Rybak M, Lomaestro B, Rotschafer J, Moellering Jr R, Craig W, Billeter M . Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2008; 66(1):82-98. DOI: 10.2146/ajhp080434. View

14.

Hing W, Bek S, Lin R, Li S . A retrospective drug utilization evaluation of vancomycin usage in paediatric patients. J Clin Pharm Ther. 2004; 29(4):359-65. DOI: 10.1111/j.1365-2710.2004.00571.x. View

15.

Sanche S, Dust W, Shevchuk Y . Vancomycin-induced neutropenia resolves after substitution with teicoplanin. Clin Infect Dis. 2000; 31(3):824-5. DOI: 10.1086/314028. View

16.

Svetitsky S, Leibovici L, Paul M . Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009; 53(10):4069-79. PMC: 2764163. DOI: 10.1128/AAC.00341-09. View

17.

Shah R, Musthaq A, Khardori N . Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report. J Med Case Rep. 2009; 3:7290. PMC: 2726558. DOI: 10.4076/1752-1947-3-7290. View

18.

Rocha J, Kondo W, Baptista M, da Cunha C, Martins L . Uncommon vancomycin-induced side effects. Braz J Infect Dis. 2002; 6(4):196-200. DOI: 10.1590/s1413-86702002000400007. View

19.

Hervas Maldonado F . [Multivariate analysis used in the investigation of antimicrobials]. Rev Esp Quimioter. 2007; 20(3):300-9. View

20.

Wallace M, Mascola J, Oldfield 3rd E . Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis. 1991; 164(6):1180-5. DOI: 10.1093/infdis/164.6.1180. View